- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 03.12.25 | ZyVersa Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 19.11.25 | ZyVersa Therapeutics GAAP EPS of -$2.56, | 1 | Seeking Alpha | ||
| 19.11.25 | ZyVersa Therapeutics Reports Third Quarter 2025 Financial Results | 135 | GlobeNewswire (Europe) | ZyVersa is advancing a therapeutic development pipeline with multiple programs built around its two proprietary technologies - Cholesterol Efflux Mediator VAR 200 for treatment of kidney diseases... ► Artikel lesen | |
| 19.11.25 | ZyVersa Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 19.11.25 | ZyVersa Therapeutics, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 14.11.25 | ZyVersa Therapeutics, Inc. - NT 10-Q, Notification of inability to timely file Form 10-Q or 10-QSB | - | SEC Filings | ||
| 15.10.25 | ZyVersa Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 06.10.25 | NSE - ZyVersa Therapeutics, Inc. - 25, Notification of the removal from listing and registration of matured, redeemed or retired securities | 2 | SEC Filings | ||
| ZYVERSA THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 18.09.25 | ZyVersa Therapeutics: Aktie wird von der Nasdaq dekotiert, Handel an OTCQB läuft weiter | 6 | Investing.com Deutsch | ||
| 18.09.25 | ZyVersa Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 10.09.25 | ZyVersa Therapeutics Highlights Data Reinforcing the Potential of Inflammasome Inhibitors to Attenuate Progression of Type 2 Diabetes and Improve Associated Long-term Cardiovascular Outcomes | 1 | GlobeNewswire (USA) | ||
| 03.09.25 | ZyVersa Therapeutics Highlights Lipidomic Data in Alport Syndrome and DKD Reinforcing the Need for Drugs to Attenuate Damaging Renal Lipid Accumulation to Mitigate Disease Progression | 203 | GlobeNewswire (Europe) | ZyVersa is developing Cholesterol Efflux Mediator VAR 200 to mediate removal of damaging excess cholesterol and other lipids from the kidneys' filtration system. VAR 200 directly removes lipids from... ► Artikel lesen | |
| 13.08.25 | ZyVersa Therapeutics Reports Second Quarter 2025 Financial Results and Highlights Key Near-term Value-building Milestones | 485 | GlobeNewswire (Europe) | KEY HIGHLIGHTS First clinical site for Phase 2a clinical trial for Cholesterol Efflux Mediator VAR 200 in patients with diabetic kidney disease (DKD) was activated June 2025; patient screening... ► Artikel lesen | |
| 21.07.25 | ZyVersa Therapeutics CEO Issues Mid-year Shareholder Letter Highlighting Recent Corporate Developments and R&D Progress | 216 | GlobeNewswire (Europe) | WESTON, Fla., July 21, 2025 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA; "ZyVersa"), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment... ► Artikel lesen | |
| 08.07.25 | ZyVersa Therapeutics Supports FDA-Authorized Emergency Compassionate Use of Cholesterol Efflux Mediator VAR 200 in a Patient with ApoCII Amyloidosis | 593 | GlobeNewswire (Europe) | ApoCII amyloidosis, resulting from abnormal organ deposition of toxic fibrillar amyloid proteins, is an ultra-rare condition that mostly affects the kidneys and manifests with protein spillage into... ► Artikel lesen | |
| 26.06.25 | ZyVersa Therapeutics Announces First Clinical Site Activation, Initiating Patient Recruitment for Cholesterol Efflux Mediator VAR 200's Phase 2a Clinical Trial in Patients with Diabetic Kidney Disease (DKD) | 231 | GlobeNewswire (Europe) | Initiation of patient recruitment marks a key milestone in the development of VAR 200, a potential first-in-class treatment for kidney disease addressing renal lipotoxicity.There are no available... ► Artikel lesen | |
| 20.05.25 | ZyVersa Therapeutics Highlights Published Study Reinforcing That Microglia-driven Inflammation Is Pivotal in Development of Parkinson's and Alzheimer's Diseases | 188 | GlobeNewswire (Europe) | Study results corroborate our recently published data demonstrating the critical role of microglial-driven inflammation in promoting accumulation and spread of toxic phosphorylated alpha-synuclein... ► Artikel lesen | |
| 12.05.25 | ZyVersa Therapeutics Reports First Quarter 2025 Financial Results and Highlights Pipeline Progress | 210 | GlobeNewswire (Europe) | KEY HIGHLIGHTS First patient expected to start therapy by end of Q2-2025 in Phase 2a proof-of concept clinical trial for Cholesterol Efflux MediatorTM VAR 200 in patients with diabetic kidney disease... ► Artikel lesen | |
| 24.04.25 | ZyVersa Therapeutics CEO Issues Shareholder Letter Announcing Transformative R&D Trends for Inflammasome Inhibitors, and Provides Update on Inflammasome ASC Inhibitor IC 100's Development Status | 118 | GlobeNewswire (Europe) | WESTON, Fla., April 24, 2025 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA; "ZyVersa"), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment... ► Artikel lesen | |
| 08.04.25 | ZyVersa Therapeutics CEO Issues Shareholder Letter on PARASOL Recommendations Expected to Reduce Drug Development Barrier for Rare Kidney Disease, Focal Segmental Glomerulosclerosis (FSGS) | 276 | GlobeNewswire (Europe) | WESTON, Fla., April 08, 2025 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA; "ZyVersa"), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment... ► Artikel lesen |
1 2 Weiter >>
22 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 88,75 | +2,31 % | BioNTech Aktie: Die Wende naht! Golden Cross! | © Foto: 2026 BioNTech SE. Alle Recht vorbehalten.Fast wie in der Serie "Game of Thrones", wo der Winter naht, könnte bei BioNTech die Wende nahen. Nach dem Kursrausch in der Corona-Ära folgte der brutale... ► Artikel lesen | |
| QIAGEN | 41,135 | +1,07 % | Shortseller-Positionen aktuell: freenet, Gerresheimer, Hypoport, Qiagen, Renk, Suss MicroTec, TeamViewer | Wer Aktien leerverkauft, also auf fallende Kurse spekuliert (Shortselling), unterliegt bestimmten Transparenzpflichten. Aktuelle Meldungen über Leerverkäufe geben Aufschluss darüber. Diese Vorgaben... ► Artikel lesen | |
| EVOTEC | 5,492 | +3,54 % | Evotec Aktie: Kann man "diesem Braten wirklich trauen"? | © Foto: Julia Koblitz auf Unsplash (Symbolbild)Neue Aufträge, ein Sparprogramm und frische Analystenkommentare. Die Evotec-Aktie sendet wieder Lebenszeichen. Doch wer die Geschichte dieses Hamburger... ► Artikel lesen | |
| MODERNA | 47,450 | +10,62 % | Moderna freut sich über eine Zulassungsempfehlung der EMA für einen Kombi-Impfstoff gegen Corona und Grippe | Bei Corona-Impfstoffen war der US-Konzern Moderna noch ein Nachzügler. Anders scheint es nun bei Kombi-Impfstoffen zu laufen, die gleichzeitig vor Corona und der Grippe schützen. Dafür gibt es bisher... ► Artikel lesen | |
| IMMUNITYBIO | 8,322 | -3,37 % | IMMUNITYBIO INC im Fokus: Geduld und Klarheit gefragt | ||
| TARSUS PHARMACEUTICALS | 76,50 | -1,20 % | Tarsus Pharmaceuticals, Inc: Tarsus Pharmaceuticals Appoints Renowned Biopharmaceutical Leader and Former Allergan CEO, David Pyott, to its Board of Directors | IRVINE, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) today announced the appointment of David E. I. Pyott, a distinguished leader in the global biopharmaceutical... ► Artikel lesen | |
| OCUGEN | 1,697 | +6,83 % | Ocugen Announces Phase 3 liMeliGhT Enrollment Completion for OCU400, a Novel Modifier Gene Therapy for Broad Retinitis Pigmentosa | Enrollment for liMeliGhT, the first and largest gene therapy registrational trial for broad retinitis pigmentosa (RP) patients, was completed, reflecting strong interest from investigators and patientsTopline... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 23,910 | -3,43 % | Arcutis Biotherapeutics, Inc.: Arcutis Begins Enrolling Phase 1a/1b Study Evaluating ARQ-234, a CD200R Agonist, in Healthy Volunteers and Adults With Atopic Dermatitis | Phase 1a/1b, first-in-human study to evaluate safety and tolerability for investigational ARQ-234 in healthy volunteers and adults with moderate to severe atopic dermatitisARQ-234 is a potent fusion-protein... ► Artikel lesen | |
| VALNEVA | 4,698 | +6,05 % | Original-Research: Valneva (von First Berlin Equity Research GmbH): Buy | Original-Research: Valneva - von First Berlin Equity Research GmbH
25.02.2026 / 17:11 CET/CEST
Veröffentlichung einer Research, übermittelt durch EQS News - ein Service der EQS Group.
Für den Inhalt... ► Artikel lesen | |
| CAPRICOR | 22,800 | +2,47 % | Capricor Therapeutics Provides Regulatory Update on Deramiocel BLA Following FDA Review of HOPE-3 Topline Data | FDA has requested the HOPE-3 clinical study report (CSR) as part of the BLA review processCompany expects to submit updates to the BLA in February 2026 to support continued FDA review SAN DIEGO,... ► Artikel lesen | |
| OLEMA PHARMACEUTICALS | 23,370 | -2,71 % | Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| STRYKER | 330,00 | -0,33 % | Stryker highlights new additions to Mako, Triathlon portfolios at AAOS | ||
| ARVINAS | 12,980 | -3,06 % | Arvinas, Inc. (ARVN) Makes Significant Progress on Oncology and Neurology Trials | ||
| JANUX THERAPEUTICS | 13,050 | -2,76 % | Truist cuts Janux Therapeutics stock price target on competition | ||
| BB BIOTECH | 50,50 | +0,60 % | BB Biotech: Von Innovation zu Wertrealisierung - Der Biotech-Markt in einer neuen Phase | Nach mehreren Jahren, die von erhöhten Kapitalkosten, Bewertungsdruck und ausgeprägter Risikoaversion geprägt waren, hat sich das Umfeld seit dem vergangenen Jahr spürbar stabilisiert. Finanzierungsbedingungen... ► Artikel lesen |
Das Unternehmen ZYVERSA THERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 0,310 Euro und damit -0,42 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ZYVERSA THERAPEUTICS INC finden Sie auf Wallstreet Online.